Ethic Inc. Has $5.07 Million Holdings in Sanofi (NASDAQ:SNY)

Ethic Inc. grew its holdings in Sanofi (NASDAQ:SNY - Free Report) by 26.5% in the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 105,127 shares of the company's stock after acquiring an additional 22,001 shares during the quarter. Ethic Inc.'s holdings in Sanofi were worth $5,070,000 at the end of the most recent reporting period.

Several other large investors also recently modified their holdings of the business. Synergy Asset Management LLC bought a new position in Sanofi in the fourth quarter valued at approximately $25,000. McClarren Financial Advisors Inc. raised its holdings in shares of Sanofi by 952.6% in the fourth quarter. McClarren Financial Advisors Inc. now owns 600 shares of the company's stock valued at $28,000 after purchasing an additional 543 shares during the last quarter. Bessemer Group Inc. raised its holdings in shares of Sanofi by 59.8% in the fourth quarter. Bessemer Group Inc. now owns 647 shares of the company's stock valued at $32,000 after purchasing an additional 242 shares during the last quarter. Lee Danner & Bass Inc. acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $31,000. Finally, Sierra Ocean LLC acquired a new stake in shares of Sanofi in the fourth quarter valued at approximately $44,000. 14.04% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

A number of analysts have recently issued reports on SNY shares. BNP Paribas started coverage on shares of Sanofi in a report on Tuesday, April 15th. They issued an "outperform" rating and a $65.00 price objective on the stock. Hsbc Global Res upgraded shares of Sanofi to a "strong-buy" rating in a report on Monday, April 28th. Deutsche Bank Aktiengesellschaft upgraded shares of Sanofi from a "sell" rating to a "hold" rating in a report on Thursday, January 30th. Sanford C. Bernstein upgraded shares of Sanofi to a "strong-buy" rating in a report on Thursday, January 30th. Finally, The Goldman Sachs Group assumed coverage on shares of Sanofi in a report on Friday, March 21st. They issued a "neutral" rating and a $65.00 price objective on the stock. Three equities research analysts have rated the stock with a hold rating, two have given a buy rating and three have issued a strong buy rating to the company's stock. According to MarketBeat.com, the stock currently has a consensus rating of "Buy" and a consensus price target of $63.33.

Sanofi Stock Up 2.3%

SNY traded up $1.16 during trading on Monday, reaching $51.06. 2,797,149 shares of the stock were exchanged, compared to its average volume of 2,371,967. The stock has a market cap of $128.99 billion, a P/E ratio of 20.51, a price-to-earnings-growth ratio of 1.01 and a beta of 0.55. Sanofi has a twelve month low of $45.80 and a twelve month high of $60.12. The stock's 50 day moving average price is $54.06 and its two-hundred day moving average price is $51.97. The company has a debt-to-equity ratio of 0.15, a quick ratio of 1.14 and a current ratio of 1.46.

Sanofi (NASDAQ:SNY - Get Free Report) last issued its earnings results on Thursday, April 24th. The company reported $0.94 earnings per share for the quarter, topping analysts' consensus estimates of $0.90 by $0.04. The business had revenue of $10.41 billion for the quarter, compared to the consensus estimate of $9.79 billion. Sanofi had a net margin of 12.77% and a return on equity of 25.61%. The firm's revenue for the quarter was down 11.0% on a year-over-year basis. During the same period in the previous year, the company earned $1.78 earnings per share. Equities analysts expect that Sanofi will post 4.36 EPS for the current year.

Sanofi Increases Dividend

The business also recently disclosed an annual dividend, which will be paid on Thursday, June 12th. Stockholders of record on Friday, May 9th will be given a $2.0369 dividend. The ex-dividend date is Friday, May 9th. This is a positive change from Sanofi's previous annual dividend of $1.48. This represents a dividend yield of 3.1%. Sanofi's dividend payout ratio is presently 57.14%.

Sanofi Profile

Sanofi, a healthcare company, engages in the research, development, manufacture, and marketing of therapeutic solutions in the United States, Europe, Canada, and internationally. It operates through Pharmaceuticals, Vaccines, and Consumer Healthcare segments. The company provides specialty care, such as DUPIXENT, neurology and immunology, rare diseases, oncology, and rare blood disorders; medicines for diabetes and cardiovascular diseases; and established prescription products.